Tesamorelin Co
Start provider review

FDA-approved drug

Tesamorelin shrinks the fat you cannot pinch. Stop it, and that fat comes back.

This is the one growth-hormone-axis peptide with a real FDA approval and real phase 3 trials: visceral fat, measured by CT scan, fell 15.2% and 10.9% in 26 weeks. The same label that grants the approval calls the drug weight neutral, limits it to HIV-associated lipodystrophy, and mandates IGF-1 and glucose monitoring. The trials that proved it works also proved the fat returns within 26 weeks of stopping. We document all of it, every number linked to its source.

Start provider reviewBrowse the guides
  • 1FDA-approved use, and we name its exact boundary
  • 34fetch-verified sources, every one peer-reviewed or government
  • 14studies in the graded evidence table, species labeled on every row
  • 12of those rows are human trials; the rat rows say rat

Online care, from intake to delivery

Tesamorelin care, made simple

Choose your plan, complete a private medical intake, and connect with a licensed provider. If prescribed, treatment ships discreetly to your door.

Tesamorelin care catalog product image
Compounded injectable treatmentPrepared after approval
Catalog image. Dispensed product and packaging may vary by pharmacy.

Your care plan includes

Everything you need to get started

From$206.10per month
Licensed providerMedical reviewIf prescribedTreatment includedAt no added costDiscreet shippingWhen you need itOrder support
Choose your planChange or cancel future refills anytime
Due today$224.10then monthly

Encrypted checkout • provider review required • shipping included

  1. 01
    Choose your planSelect the supply and refill preference that works for you.
  2. 02
    Complete your intakeShare your health history in our private, secure flow.
  3. 03
    Provider reviewIf appropriate, your prescription is prepared and shipped.

Prescription treatment requires an online medical evaluation. A provider will determine whether treatment is medically appropriate; approval is not guaranteed.

Key facts

  • StatusFDA-approved drug
  • Stabilizationtrans-3-hexenoyl modification confers DPP-4 resistance vs natural GHRHsource
  • Tmax0.15 h (median, ~9 minutes)source
  • Bioavailability<4% (subcutaneous, 2 mg, healthy adults)source
  • Volume of distribution4.8 +/- 1.9 L/kgsource
  • Population noteAUC ~34% higher in HIV-infected patients than healthy subjectssource
  • RouteSubcutaneous injection, abdomen only, once dailysource
  • PharmacodynamicsStimulates pulsatile endogenous GH; raises IGF-1 and IGFBP-3; other pituitary axes unchanged in trialssource
  • ClassGHRH analog (stabilized GRF 1-44)FDA labelsource
  • Approved useExcess abdominal fat in HIV-associated lipodystrophy (adults)FDA labelsource
  • Dose (current labels)1.4 mg (SV) or 1.28 mg (WR) SC once daily, abdomenFDA labelsource
  • Half-life8 to 11 minutesFDA labelsource
  • Pivotal resultVAT -15.2% and -10.9% vs placebo at 26 weeksHuman RCTsource
  • Weight effectWeight neutral (label wording)FDA labelsource
  • On stoppingVisceral fat reaccumulates within 26 weeksHuman RCTsource
  • Label monitoringIGF-1 during therapy; glucose before and duringFDA labelsource
  • Molecular identityC221H366N72O67S, 5135.9 Da, PubChem CID 16137828Chemical referencesource

Read the full Tesamorelin monograph

Browse by topic

Everything on Tesamorelin, organized the way you research it.

Evidence20 articlesSourcing15 articlesDosing11 articlesComparisons9 articlesSafety8 articles

Free Tesamorelin tools

Practical calculators and references, each scoped and sourced.

T-01Reconstitution calculatorConcentration, draw volume, U-100 syringe units, and doses per vial from vial size, water volume, and dose.T-02Study dose explorerEvery dose reported in the published literature for this compound, filterable by species and route, each row sourced.T-03IGF-1 monitoring guideTesamorelin is unusual among GH-axis peptides in having its lab work written into federal labeling.

study rows by species, from the evidence table

A folded pale gray towel and a glass water bottle with a wooden cap on a light wooden bench in cool morning light.
A pale ceramic bowl of green apples and a glass carafe of water on a gray stone counter in soft light.

All guides

63 in-depth, individually cited guides.

Evidence 20 guides

How long does tesamorelin take to work?Phase 3 data show visceral fat drops start by week 14; full 26-week trials show ~15-18% VAT reduction. Here's the real timeline, by outcome.Updated 2026-07-25Read guide →
1 closely related:How long does it take for tesamorelin to work?
Tesamorelin: animal studies vs human clinical evidenceTesamorelin's approval rests on two phase 3 human trials, not animal data. See what's proven, what's extrapolated, and what's still off-label.Updated 2026-07-25Read guide →
Tesamorelin before and after claims: what the trials actually showTesamorelin trials show an 18% average visceral fat drop at 26 weeks in HIV lipodystrophy. Here's what before/after photos leave out, sourced to phase 3 data.Updated 2026-07-25Read guide →
Tesamorelin human studies: what the trials actually showTesamorelin's phase 3 trials cut visceral fat about 18% in HIV lipodystrophy. Here's what the human evidence covers, and where it stops.Updated 2026-07-25Read guide →
Tesamorelin mechanism of action: how it works in the bodyTesamorelin is a GHRH analogue that stimulates the pituitary to release GH in pulses. Here's the receptor biology behind its FDA-approved fat-reduction effect.Updated 2026-07-25Read guide →
Best tesamorelin peptide: how to actually evaluate oneThere's no "best" tesamorelin brand, only FDA-approved Egrifta and compounded copies. Here's the real evidence, dosing and sourcing checklist before you buy.Updated 2026-07-24Read guide →
Can women take tesamorelin peptide? what the evidence saysTesamorelin (Egrifta) is FDA-approved for HIV lipodystrophy in adults, not sex-restricted. Here's what the trial data on women actually shows, and what's off-label.Updated 2026-07-24Read guide →
Does tesamorelin cause cancer? what the trial data showsTesamorelin's phase 3 trials found no increased cancer signal, but the label carries an IGF-1 caution and cancer patients were excluded. Here's the actual evidence.Updated 2026-07-24Read guide →
How to get tesamorelin: the legal, provider-reviewed routeTesamorelin (Egrifta) is FDA-approved by prescription only, for HIV lipodystrophy. Here's the real path to get it, on-label or off-label, and what to skip.Updated 2026-07-24Read guide →
Tesamorelin: the FDA-approved GHRH analogue, explainedTesamorelin (Egrifta) is FDA-approved for HIV lipodystrophy visceral fat. Phase 3 data, dosing, off-label use, and safety facts, sourced and explained.Updated 2026-07-24Read guide →
Tesamorelin clinical trials: what the phase 3 data actually showsTesamorelin (Egrifta) cut visceral fat about 15-18% in phase 3 HIV trials vs placebo. Here's the trial evidence, what it covers, and what it doesn't.Updated 2026-07-24Read guide →
Tesamorelin in women: what the evidence actually showsEgrifta's phase 3 trials for HIV lipodystrophy enrolled few women. Here's the real female-specific evidence, dosing, and off-label questions answered.Updated 2026-07-24Read guide →
Tesamorelin nasal spray: is there a clinical trial?No approved tesamorelin nasal spray exists. FDA approval covers Egrifta injection only, backed by two phase 3 trials. Here's what the evidence actually shows.Updated 2026-07-24Read guide →
Tesamorelin before and after: what the trial data actually showPhase 3 trials found ~18% visceral fat reduction at 26 weeks with tesamorelin. Here's the real timeline, what changes, and what doesn't.Updated 2026-07-24Read guide →
Tesamorelin peptide stacks: what the evidence actually supportsTesamorelin is FDA-approved alone, for one indication. Stacking with IGF-1 LR3 or other peptides has no phase 3 data. Here's what's actually known.Updated 2026-07-24Read guide →
Tesamorelin results: what the clinical research actually showsTesamorelin cut visceral fat about 18% in phase 3 trials for HIV lipodystrophy. Here's the real evidence, what it doesn't show, and what's still off-label.Updated 2026-07-24Read guide →
Tesamorelin timeline: what to expect week by weekPhase 3 data show visceral fat drops start by week 14 and hold through 26-52 weeks. Here's the realistic tesamorelin timeline, dosed on real trial evidence.Updated 2026-07-24Read guide →
What does tesamorelin actually do in the body?Tesamorelin is FDA-approved for HIV lipodystrophy: phase 3 trials show real visceral fat drops. Here's what it does, and doesn't do, backed by the data.Updated 2026-07-24Read guide →
When to take tesamorelin: timing, cycle length, and dosingTesamorelin is dosed once daily at bedtime by subcutaneous injection. Here's what the phase 3 trials actually say about timing, cycles, and food.Updated 2026-07-24Read guide →

Sourcing 15 guides

Does tesamorelin need to be refrigerated? Storage rules explainedYes. Reconstituted tesamorelin (Egrifta) must stay refrigerated at 2-8°C and gets used within 14 to 30 days. Here's what the label and studies actually say.Updated 2026-07-25Read guide →
Is tesamorelin FDA approved? Yes, for one specific useTesamorelin (Egrifta) is FDA approved, but only to reduce excess visceral fat in HIV lipodystrophy. Here's what the approval covers and what it doesn't.Updated 2026-07-25Read guide →
Tesamorelin certificate of analysis explainedWhat a tesamorelin COA should show, why FDA-approved Egrifta doesn't need one for patients, and how to read purity, sterility, and identity data.Updated 2026-07-25Read guide →
Tesamorelin cost: what egrifta and generic vials actually runEgrifta list price tops $5,000/month before coupons. Compounded tesamorelin runs far less. Here's what actually drives tesamorelin cost and what to check first.Updated 2026-07-25Read guide →
Tesamorelin cost and pricing: what it actually costs in 2026Brand Egrifta runs well over $1,000/month before insurance; compounded tesamorelin costs far less but carries different risk. Here's the real pricing breakdown.Updated 2026-07-25Read guide →
Tesamorelin legal status: FDA-approved use vs off-label realityTesamorelin (Egrifta) is FDA-approved only for HIV lipodystrophy. Here's what that actually means for prescriptions, compounding, and off-label use.Updated 2026-07-25Read guide →
Tesamorelin prescription requirements: what you actually needTesamorelin (Egrifta) is prescription-only in the US, FDA-approved only for HIV lipodystrophy. Here's what a legal prescription requires, and where off-label use stands.Updated 2026-07-25Read guide →
Best peptide to stack with tesamorelin: a reality checkNo approved trial ever tested tesamorelin stacked with another peptide. Here's what the phase 3 data actually covers, and what stacking really means for risk.Updated 2026-07-24Read guide →
Best place to buy tesamorelin: a buyer's reality checkEgrifta is FDA-approved by prescription only; compounded tesamorelin fills the off-label gap. Here's what actually determines a safe, legitimate source.Updated 2026-07-24Read guide →
1 closely related:Best place to buy tesamorelin online: a buyer's reality check
How to get tesamorelin peptide: the legal, evidence-based routesTesamorelin (Egrifta) is FDA-approved by prescription only for HIV lipodystrophy. Here's how prescriptions, compounding pharmacies, and telehealth actually work.Updated 2026-07-24Read guide →
How to verify tesamorelin quality before you inject itEgrifta is FDA-approved with phase 3 data; compounded tesamorelin is not. Here's exactly how to check purity, sourcing, and paperwork before you buy.Updated 2026-07-24Read guide →
Tesamorelin compounding pharmacy vs research supplierTesamorelin is FDA-approved only as branded Egrifta. Compare compounded 503A/503B pharmacy sourcing against research-chemical sellers before you buy.Updated 2026-07-24Read guide →
Tesamorelin peptide near me: what to actually look forSearching "tesamorelin peptide near me"? Here's what FDA approval covers, why sourcing matters more than location, and how to find a legitimate provider.Updated 2026-07-24Read guide →
Tesamorelin purity and testing: what buyers need to checkEgrifta is FDA-approved, but compounded tesamorelin isn't. Here's what purity testing means, why it matters, and how to check a source before you buy.Updated 2026-07-24Read guide →

Dosing 11 guides

Best time to take tesamorelin peptide: what the trials showPhase 3 trials dosed tesamorelin nightly before bed. Here's why timing matters, what the evidence actually covers, and what's off-label guesswork.Updated 2026-07-25Read guide →
How to reconstitute tesamorelin: a step by step guidetesamorelin (egrifta) ships as a lyophilized powder that must be mixed with sterile water before injection. here's the exact process, step by step.Updated 2026-07-25Read guide →
Tesamorelin cycle length: how long should a course run?The phase 3 trials ran tesamorelin for 26 to 52 weeks continuously, not in on/off cycles. Here's what the trial data actually supports.Updated 2026-07-25Read guide →
Tesamorelin half life: how long it stays active in the bodyTesamorelin's plasma half life is roughly 25 to 38 minutes. Here's what that means for dosing schedule, timing, injection frequency, and clearance.Updated 2026-07-25Read guide →
Tesamorelin how to inject: a step-by-step protocol guideHow to reconstitute and inject tesamorelin correctly, based on the phase 3 trial protocol (2 mg SC daily) behind FDA-approved Egrifta. Step-by-step, sourced.Updated 2026-07-25Read guide →
Tesamorelin injection sites: where and how to injectTesamorelin (Egrifta) is injected subcutaneously into the abdomen, with sites rotated daily. Here's the FDA label guidance and what the phase 3 trials actually used.Updated 2026-07-25Read guide →
Tesamorelin storage and shelf life, refrigeration rulesHow to store tesamorelin before and after reconstitution: fridge temps, freezer stability, powder shelf life, and when a reconstituted vial actually goes bad.Updated 2026-07-25Read guide →
How to take tesamorelin peptide: the actual injection stepsTesamorelin is injected subcutaneously once daily, 2mg reconstituted, on an empty stomach at night. Here is the real phase 3 protocol and how to follow it.Updated 2026-07-24Read guide →
Tesamorelin dosage: the approved 2mg protocol, explainedThe FDA-approved tesamorelin dose is 2mg/day subcutaneous. Here's the trial evidence, mixing math for 2mg and 5mg vials, and why more isn't better.Updated 2026-07-24Read guide →
Tesamorelin dosage calculator: how to work out your doseThe approved tesamorelin dose is 2 mg/day by injection. Here's how a reconstitution calculator works, why it can't replace a prescriber, and what the trials actually tested.Updated 2026-07-24Read guide →
Tesamorelin reconstitution: how to mix it correctlyStep-by-step tesamorelin reconstitution: bacteriostatic water amount, mixing technique, storage life after reconstitution, and what the labeling actually says.Updated 2026-07-24Read guide →

Comparisons 9 guides

Tesamorelin vs Egrifta: what's actually the difference?Egrifta is the FDA-approved brand of tesamorelin. There's no pharmacological difference, just legal status, source, and price. Here's the full comparison.Updated 2026-07-25Read guide →
Tesamorelin vs ipamorelin: what the evidence actually showsTesamorelin is FDA-approved with phase 3 data for HIV lipodystrophy; ipamorelin has no FDA approval and no comparable human trials. Here's the real gap.Updated 2026-07-25Read guide →
Hexarelin vs tesamorelin: what the evidence actually showsTesamorelin is FDA-approved with phase 3 trial data for HIV lipodystrophy. Hexarelin isn't approved for anything. Here's the real evidence gap.Updated 2026-07-24Read guide →
IGF-1 LR3 vs tesamorelin: what the evidence actually saysTesamorelin is FDA-approved with phase 3 data for HIV lipodystrophy. IGF-1 LR3 has no such trials and no legal path to compounding. Here's the real comparison.Updated 2026-07-24Read guide →
Tesamorelin stacks: what the evidence actually supportsTesamorelin has phase 3 data alone, not in combination. Here's what's known, what's guessed, and what stacking with other peptides actually risks.Updated 2026-07-24Read guide →
Tesamorelin vs CJC-1295: what the evidence actually saysTesamorelin is FDA-approved for HIV lipodystrophy with phase 3 data. CJC-1295 has no FDA approval and no human trials. Here's the real comparison.Updated 2026-07-24Read guide →
Tesamorelin vs growth hormone: what the evidence showsTesamorelin is an FDA-approved GHRH analogue for HIV lipodystrophy; HGH is a hormone with broader, riskier off-label use. Compare data, dosing, and safety.Updated 2026-07-24Read guide →
Tesamorelin vs HGH: comparing the evidence, dosing, and riskTesamorelin is FDA-approved for one indication with phase 3 trial data; HGH for anti-aging is off-label and unapproved. Compare evidence, dosing, and safety.Updated 2026-07-24Read guide →
Tesamorelin vs sermorelin: what the evidence actually showsTesamorelin has FDA approval and phase 3 trial data for visceral fat in HIV lipodystrophy. Sermorelin does not. Here's the head-to-head comparison.Updated 2026-07-24Read guide →

Safety 8 guides

Is tesamorelin safe? what the FDA trials actually showTesamorelin is FDA-approved with phase 3 safety data in HIV lipodystrophy. Here's what the trials found on side effects, glucose, and who should avoid it.Updated 2026-07-25Read guide →
Tesamorelin and athletes: drug testing status explainedTesamorelin is a GHRH analogue banned in competitive sport under WADA's S2 category. Here's the detection science, testing reality, and what athletes should know.Updated 2026-07-25Read guide →
Tesamorelin and blood work: what to test and whenTesamorelin needs baseline and follow-up labs: IGF-1, glucose, A1c, liver enzymes. Here's what the phase 3 trials actually monitored and why it matters.Updated 2026-07-25Read guide →
Tesamorelin contraindications: who should not use itEgrifta's label warns against use in active cancer, pituitary/pregnancy, and hypersensitivity to tesamorelin or mannitol. Full contraindication breakdown here.Updated 2026-07-25Read guide →
Tesamorelin side effects: what the phase 3 trials actually foundFDA trials found injection site reactions in about 25% of patients and joint pain in about 13%. Here's the full side effect profile of tesamorelin, cited.Updated 2026-07-25Read guide →
Tesamorelin drug interactions: what actually mattersTesamorelin has no major CYP-based drug interactions, but it can raise blood sugar and change how other drugs are dosed. Here's the real interaction list.Updated 2026-07-24Read guide →
Tesamorelin long term side effects: what the trials showEgrifta's phase 3 safety extension ran 52 weeks. Here's what long term tesamorelin side effects look like in the actual trial data, and what's still unknown.Updated 2026-07-24Read guide →
Tesamorelin peptide side effects: what the trials actually showInjection site reactions hit roughly 25-35% of tesamorelin users in trials. Here's the full side effect profile from the phase 3 data, plain and unranked.Updated 2026-07-24Read guide →
A slate blue ceramic cup beside a closed gray linen-bound notebook on a pale ash desk in cool window light.
An open notebook with blank pages beside a stack of plain paper and a small slate blue ceramic cup on a pale desk.

Get the label-vs-marketing brief before you talk to any clinic

One email: the approved-use boundary, the monitoring checklist, the stop-and-regain data, and the study-dose table, all cited. Updates only when the label or a new trial changes something. No dosing advice by email. Unsubscribe anytime.

Free. No spam, unsubscribe anytime. Your address is used for this brief and nothing else.

Start provider review